Amgen (AMGN) Tops Q1 EPS by 8c, Updates FY Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. PTC
2. NVDA
3. PCVX
4. SPY
5. META
6. MSFT
7. USO
8. AMD
9. GMAB
10. ATH

Go back to Amgen (AMGN) Tops Q1 EPS by 8c, Updates FY Guidance

Amgen Reports First Quarter 2019 Financial Results

April 30, 2019 4:01 PM EDT

THOUSAND OAKS, Calif., April 30, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the first quarter of 2019. Key results include:

Total revenues were unchanged at $5.6 billion in comparison to the first quarter of 2018. Product sales declined 1 percent globally. New and recently launched products including Prolia® (denosumab), Repatha® (evolocumab) and KYPROLIS® (carfilzomib) showed double-digit growth.GAAP earnings per share (EPS) decreased 2 percent to $3.18 driven by higher total operating expenses, offset partially by lower weighted-average shares outstanding. GAAP operating income decreased 9... More